Genmab A/S (NASDAQ:GMAB) Receives $45.20 Consensus PT from Analysts

Genmab A/S (NASDAQ:GMAB) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $45.20.

GMAB has been the topic of several research analyst reports. BMO Capital Markets restated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th.

Institutional Trading of Genmab A/S

A number of large investors have recently modified their holdings of the company. Two Sigma Advisers LP raised its position in shares of Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares in the last quarter. ABC Arbitrage SA bought a new stake in Genmab A/S during the fourth quarter worth approximately $3,692,000. AIMZ Investment Advisors LLC acquired a new stake in Genmab A/S in the fourth quarter worth approximately $3,525,000. Raymond James Financial Inc. bought a new position in Genmab A/S during the 4th quarter valued at $2,463,000. Finally, Y Intercept Hong Kong Ltd increased its position in shares of Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock valued at $1,538,000 after purchasing an additional 58,048 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Trading Down 1.6 %

Shares of GMAB opened at $18.69 on Friday. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88. The firm has a market cap of $12.37 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.54 and a beta of 0.96. The stock has a 50 day moving average of $20.84 and a 200-day moving average of $23.37.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.